If you or a loved one is taking Tysabri and concerned about progressive multifocal leukoencephalopathy (PML), recognizing early signs is critical. The medical community has long studied the link between immunosuppressive therapies and viral reactivation, providing a framework for understanding individual risk. This page outlines the key symptoms and evidence that can help you stay informed.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV) and typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems, often leading to severe disability or death. Three factors are known to increase the risk of PML in TYSABRI-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking TYSABRI to PML involves the drug's inhibition of alpha-4 integrin, which prevents immune cells from crossing the blood-brain barrier. This reduces immune surveillance in the central nervous system, allowing JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The adequacy of warnings regarding TYSABRI and PML is a central issue in litigation. The boxed warning explicitly states that TYSABRI increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, with dosing withheld immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, TYSABRI is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to be enrolled, read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals must evaluate patients at specified intervals and report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether the warnings were sufficient to inform patients and prescribers of the full scope of risk, particularly given the severity and often fatal outcome of PML.
For affected patients in California, settlement-related considerations involve the statute of limitations for filing claims. In California, the statute of limitations for personal injury claims generally is two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For claims involving PML associated with TYSABRI, the timeline between exposure and documented harm is critical. PML can develop after months to years of TYSABRI treatment, with risk increasing beyond two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The onset of symptoms may be gradual, and diagnosis can be delayed, complicating the determination of when the statute of limitations begins to run. Patients who have been diagnosed with PML after receiving TYSABRI should consult with legal counsel promptly to assess their individual circumstances and ensure compliance with applicable deadlines. Settlement considerations also include the potential for compensation for medical expenses, lost income, pain and suffering, and other damages. The severity of PML, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), underscores the importance of timely legal action. Patients and their families should be aware that the TOUCH program requires ongoing monitoring and reporting, and that any signs or symptoms suggestive of PML should prompt immediate medical evaluation and withholding of TYSABRI (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early diagnosis and intervention may improve outcomes, but the prognosis for PML remains poor. In summary, the medical evidence clearly establishes that TYSABRI increases the risk of PML, with identifiable risk factors and a well-understood mechanistic pathway. The adequacy of warnings is addressed in the prescribing information and the TOUCH program, but litigation may examine whether these measures were sufficient. For California patients, the statute of limitations and the timeline between exposure and harm are key factors in settlement considerations. Affected individuals should seek legal advice promptly to protect their rights.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In California, the statute of limitations for personal injury claims generally is two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For PML associated with Tysabri, the timeline between exposure and harm is critical, and patients should consult legal counsel promptly.
Three factors increase the risk: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.